Category: Medicine
Merck launches SaaS platform with 60 billion possibilities
The Aiddison drug discovery software works through Synthia retrosynthesis software application programming interface (API) integration and Merck says it combines generative artificial intelligence (AI), machine learning, and computer-aided drug design to speed up drug development. Trained on more than two decades of experimentally validated datasets from pharmaceutical research and development, Aiddison software identifies compounds from…
Read More
Q&A: Univar Solutions – sourcing and distributing pharma ingredients
As director of strategic growth and technical sales plus pharmaceutical ingredients, she has given us a comprehensive overview. OSP: Can you tell me why the distribution and sourcing of pharmaceutical ingredients is so important? MW: Interestingly, but not surprisingly, distribution got its start in ancient military times. Romans and Greeks used logistics and distribution…
Read More
Piramal Pharma has launched a high-throughput screening facility
It will add to the existing in-vitro biology capabilities with the addition of primary and secondary screening capabilities of compounds prepared at the Indian site. Piramal Pharma Limited’s Pharma Solutions (PPS) business is a leading Contract Development and Manufacturing Organization (CDMO) and with this expansion it is well positioned to provide clients with an integrated…
Read More
ObvioHealth reveals new digital therapeutics API
There is an ongoing digital shift in clinical trials, and as a result, companies are continuously striving to improve both patient experience and clinical data quality. The 21st Century Cures Act which became law in the US in December 2016, paved the way for companies to develop new technology that is capable of improving the…
Read More
Symbiosis granted MHRA license following £1 million investment
The CDMO has launched the new in-house analytical and microbiological capabilities that will enable the testing. Fully approved by the UK Regulatory Agency, the MHRA, this expansion of their service offering will strategically enhance the companies’ core sterile manufacturing service, that is also referred to as ‘fill/finish’ and provide an extensive in-house quality control (QC)…
Read More
Takeda’s Adzynma approved for prophylactic and on-demand treatment of cTTP
Takeda announced at the end of last month (November 2023) that it had been approved by the US Food and Drug Administration (FDA) on November 9, 2023. cTTP is a very rare, complex condition that can present as an acute life-threatening disorder requiring prompt diagnosis, early referral, and effective immediate and ongoing management in a…
Read More
Roquette and Qualicaps combine to expand global footprint
Qualicaps manufactures hard capsules and pharmaceutical-related equipment and is the third-largest producer for oral dosage solutions. The company is a ‘renowned global player, relying on high-quality products and a strong innovation pipeline’. It has a workforce of 1,400 employees located in different sites in Asia, Europe, and the Americas. Roquette is a family-owned global leader…
Read More
Interview: Enthought – the trials and tribulations of AI
There is still a general sense of wariness from some sectors within the life sciences and we discussed why this might be, what businesses can do to reassure clients and staff and how machines are not quite set to take people’s jobs yet. OSP: A lot of people are wary about artificial intelligence, including within…
Read More
Yseop’s impactful Generative AI capabilities helping accelerate drugs to market
At the same time, the company has announced the closing of a strategic investment round with new investor Novartis (dRx Capital) joining existing investors Eli Lilly, Next Stage AM and Wille Finance. Included in the trials, Yseop says, are many of the most notable advancements in new treatments, vaccines and medicines that have emerged recently.…
Read More
How Zizi Uzezi ‘bridges the gap’ between healthcare solutions and patients
She has successfully guided many biotech and life science companies across their end-to-end clinical development journey and has commercialized and launched over 25 pharmaceutical and medical device products into global markets. BPR: Could you give me an overview of the work you do at Bios Health Group and what the company focuses on? At Bios…
Read More
How microgravity could transform pharma manufacturing
The California-based start-up claims that, by removing gravity, they are able to make medicines that are not viable on earth. “Processing in a microgravity environment dramatically alters buoyancy, natural convection, sedimentation, phase separation and drives significant differences in transport-driven phenomena,” the company’s website reads. Essentially, Varda argues that drug formulations, both small molecules and biologics,…
Read More
‘Abstinence is not the only road to recovery’
BPR: What is Alcohol Use Disorder (AUD) and why is it a major health, social and financial problem? Alcohol Use Disorder (AUD) is a chronic disease characterized by an individual regularly consuming a quantity of alcohol which is harmful to them both physically and socioeconomically. It is believed that there are over 200 physical and…
Read More
Merck signs $70 million deal to commercialize Abbisko’s new cancer drug in China
TGCT is a benign tumor of the joints that can cause swelling, pain, stiffness, and limited mobility of the affected joints. Treatment options for this disease, which can seriously affect patients’ quality of life, are very limited. The agreement grants Merck an exclusive license to commercialize pimicotinib in mainland China, Hong Kong, Macau and Taiwan,…
Read More
Pfizer axes new weight loss pill after patients experience serious side effects
While obese patients lost significant amounts of weight, many reported high rates of side effects such as nausea and vomiting. “While the most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates were observed, up to 73% nausea, 47% vomiting and 25% diarrhea,” the pharma giant said. “High discontinuation…
Read More
Exciting opportunity to design new antibody therapy using generative AI
Announced today (December 4), the agreement will combine Absci’s Integrated Drug Creation platform with AstraZeneca’s expertise in oncology, to accelerate the discovery of a potential new cancer treatment. Absci will contribute its pioneering generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The agreement includes an upfront commitment, R&D funding,…
Read More
Not to be missed – our patient centricity in action webinar
The webinar will be broadcasting on Wednesday, December 6 at 10am CST (Chicago) and 5pm CET (Paris) and will last for 60 minutes. There will be an opportunity to submit questions throughout. We have three extremely knowledgeable and forward-looking members on the panel including Dawn Anderson from Deloitte Life Sciences & Healthcare who is managing…
Read More
Issues in data-monitoring for complex clinical trials
OSP: Can you tell us a bit more about the Sally Hollis Memorial Lecture? JV-R: The Sally Hollis Memorial Lecture was established in 2021 in memory of Professor Sally Hollis. Sally was a much-loved and highly respected member of not just the Phastar team but the wider medical statistics community. Sally was best known for…
Read More
Atropos Health forms Life Science Advisory Board with pharma experts
The life sciences advisory board indicates a continued focus on regulatory complaint and transparent methods for rapid and responsible acceleration of innovation for life science partners on the Evidence Network. The board will consist of executives from the world’s preeminent pharma companies including Moderna, Novartis among others. This latest announcement comes hot on the heels…
Read More
First eye drop for diabetic macular oedema on horizon after successful trial
During the trial, EXN407 met all endpoints and displayed ‘encouraging’ biological activity in diabetic patients with retinal eye disease. Dr Catherine Beech, CEO of Exonate, said: “The results from the EXN407 trial are very encouraging, with the data validating the hypothesis that modulating VEGF splicing can lead to clinical benefits.” Diabetic macular oedema is a…
Read More
England’s vision for an end to new cases of HIV by 2030 is on track
It has also considerably reduced HIV contraction in real-world situations across several years of use, the study found. PrEP (HIV Pre-exposure Prophylaxis) is a pre-exposure medicine – prophylaxis means to prevent infection and can reduce the risk of contracting HIV when taken as instructed. PrEP contains existing HIV treatment drugs tenofovir disoproxil and emtricitabine and…
Read More